{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:15:58Z","timestamp":1768270558082,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AMS CMU Challenge","award":["2021\/2022"],"award-info":[{"award-number":["2021\/2022"]}]},{"name":"AMS CMU Challenge","award":["2021\/2022"],"award-info":[{"award-number":["2021\/2022"]}]},{"name":"AMS CMU Challenge","award":["2021\/2022"],"award-info":[{"award-number":["2021\/2022"]}]},{"name":"CMU Fundamental Fund","award":["2565"],"award-info":[{"award-number":["2565"]}]},{"name":"CMU Fundamental Fund","award":["2565"],"award-info":[{"award-number":["2565"]}]},{"name":"CMU Fundamental Fund","award":["2565"],"award-info":[{"award-number":["2565"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Microbiol Immunol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The incidence of rabies in Thailand reached its peak in 2018 with 18 human deaths. Preexposure prophylaxis (PrEP) vaccination is thus recommended for high-risk populations. WHO has recently recommended that patients who are exposed to a suspected rabid animal and have already been immunized against rabies should receive a 1-site intradermal (ID) injection of 0.1\u00a0mL on days 0 and 3 as postexposure prophylaxis (PEP). In Thailand, village health and livestock volunteers tasked with annual dog vaccination typically receive only a single lifetime PrEP dose and subsequent boosters solely upon confirmed animal bites. However, the adequacy of a single PrEP dose for priming and maintaining immunity in this high-risk group has not been evaluated. Therefore, our study was designed to address two key questions: (1) sufficiency of single-dose PrEP\u2014to determine whether a single ID PrEP dose provides adequate long-term immune protection for high-risk individuals exposed to numerous dogs during their vaccination duties. (2) Booster efficacy for immune maturation\u2014to investigate whether one or two additional ID booster doses effectively stimulate a mature and sustained antibody response in this population. The level and persistence of the rabies antibody were determined by comparing the immunogenicity and booster efficacy among the vaccination groups. Our study demonstrated that rabies antibodies persisted for more than 180\u00a0days after cost-effective ID PrEP or the 1st or the 2nd single ID booster dose, and adequate antibody levels were detected in more than 95% of participants by CEE-cELISA and 100% by indirect ELISA. Moreover, the avidity maturation of rabies-specific antibodies occurred after the 1st single ID booster dose. This smaller ID booster regimen was sufficient for producing a sufficient immune response and enhancing the maturation of anti-rabies antibodies. This safe and effective PrEP regimen and a single visit involving a one-dose ID booster are recommended, and at least one one-dose ID booster regimen could be equitably implemented in at-risk people in Thailand and other developing countries. However, an adequate antibody level should be monitored before the booster is administered.<\/jats:p>","DOI":"10.1007\/s00430-024-00791-2","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T13:01:46Z","timestamp":1716037306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["One-dose intradermal rabies booster enhances rabies antibody production and avidity maturation"],"prefix":"10.1007","volume":"213","author":[{"given":"Chidchamai","family":"Kewcharoenwong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saranta","family":"Freeouf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnone","family":"Nithichanon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilaiwan","family":"Petsophonsakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakorn","family":"Pornprasert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woottichai","family":"Khamduang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taishi","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganjana","family":"Lertmemongkolchai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,18]]},"reference":[{"key":"791_CR1","doi-asserted-by":"crossref","unstructured":"Buchy P, Preiss S, Singh V, Mukherjee P (2017) Heterogeneity of rabies vaccination recommendations across Asia. Trop Med Infect Dis 2(3)","DOI":"10.3390\/tropicalmed2030023"},{"key":"791_CR2","doi-asserted-by":"crossref","unstructured":"Petsophonsakul WI, S (2023) One health approach to control canine Rabies in Thailand: the Chiang Mai model. In: One health for dog-mediated rabies elimination in Asia. pp 34\u201346","DOI":"10.1079\/9781800622975.0004"},{"key":"791_CR3","unstructured":"Thailand NNBo (2023) Rabies outbreak in Chiang Mai 2023 [updated 21 February 2023; cited 2023 17 July 2023]. Available from https:\/\/thainews.prd.go.th\/th\/news\/detail\/TCATG230221143326120"},{"key":"791_CR4","unstructured":"Organization WH (2018) Rabies vaccines: WHO position paper\u2014April 2018. Contract No.: WER9316"},{"issue":"3","key":"791_CR5","first-page":"1","volume":"57","author":"CE Rupprecht","year":"2008","unstructured":"Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M et al (2008) Human rabies prevention\u2013United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 57(3):1\u201328","journal-title":"MMWR Recomm Rep"},{"key":"791_CR6","doi-asserted-by":"crossref","unstructured":"Suijkerbuijk AW, Mangen MJ, Haverkate MR, Luppino FS, Bantjes SE, Visser LG et al (2020) Rabies vaccination strategies in the Netherlands in 2018: a cost evaluation. Euro Surveill 25(38)","DOI":"10.2807\/1560-7917.ES.2020.25.38.1900716"},{"key":"791_CR7","first-page":"139","volume":"351","author":"MJ Warrell","year":"2012","unstructured":"Warrell MJ (2012) Intradermal rabies vaccination: the evolution and future of pre- and post-exposure prophylaxis. Curr Top Microbiol Immunol 351:139\u2013157","journal-title":"Curr Top Microbiol Immunol"},{"key":"791_CR8","doi-asserted-by":"crossref","unstructured":"Briggs DJ, Moore SM (2021) The Route of Administration of rabies vaccines: comparing the data. Viruses 13(7)","DOI":"10.3390\/v13071252"},{"key":"791_CR9","volume-title":"WHO expert consultation on rabies: third report","author":"WH Organization","year":"2018","unstructured":"Organization WH (2018) WHO expert consultation on rabies: third report. World Health Organization, Geneva"},{"key":"791_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.prevetmed.2021.105555","volume":"199","author":"W Khamduang","year":"2022","unstructured":"Khamduang W, Hongjaisee S, Pothita T, Kongyai N, Surajinda S, Petsophonsakul W et al (2022) Antibody response to rabies pre-exposure vaccination among village health volunteers in a northern region of Thailand. Prev Vet Med 199:105555","journal-title":"Prev Vet Med"},{"issue":"2","key":"791_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.7883\/yoken.JJID.2018.248","volume":"72","author":"Y Aronthippaitoon","year":"2019","unstructured":"Aronthippaitoon Y, Samer W, Atuntee T, Thananchai H, Thongkorn K, Pongsopawijit P et al (2019) A cost effective easy competitive enzyme-linked immunosorbent assay suitable for monitoring protective immunity against the rabies virus in the serum of humans and dogs. Jpn J Infect Dis 72(2):99\u2013105","journal-title":"Jpn J Infect Dis"},{"issue":"7","key":"791_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1348-0421.2002.tb02719.x","volume":"46","author":"T Irie","year":"2002","unstructured":"Irie T, Matsuda Y, Honda Y, Morimoto K, Kawai A (2002) Studies on the escape mutants of rabies virus which are resistant to neutralization by a highly conserved conformational epitope-specific monoclonal antibody #1-46-12. Microbiol Immunol 46(7):449\u2013461","journal-title":"Microbiol Immunol"},{"issue":"36","key":"791_CR13","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1016\/j.vaccine.2022.07.037","volume":"40","author":"BP Quiambao","year":"2022","unstructured":"Quiambao BP, Lim JG, Bosch Castells V, Augard C, Petit C, Bravo C et al (2022) One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: a phase III, open-label, randomized, controlled trial to assess immunogenicity and safety. Vaccine 40(36):5347\u20135355","journal-title":"Vaccine"},{"issue":"41","key":"791_CR14","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1016\/j.vaccine.2019.08.043","volume":"37","author":"R Zhao","year":"2019","unstructured":"Zhao R, Yu P, Shan Y, Thirumeni N, Li M, Lv Y et al (2019) Rabies virus glycoprotein serology ELISA for measurement of neutralizing antibodies in sera of vaccinated human subjects. Vaccine 37(41):6060\u20136067","journal-title":"Vaccine"},{"key":"791_CR15","doi-asserted-by":"crossref","unstructured":"Mills DJ, Lau CL, Mills C, Furuya-Kanamori L (2022) Long-term persistence of antibodies and boostability after rabies intradermal pre-exposure prophylaxis. J Travel Med 29(2)","DOI":"10.1093\/jtm\/taab188"},{"issue":"1","key":"791_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1086\/520143","volume":"29","author":"A Sabchareon","year":"1999","unstructured":"Sabchareon A, Lang J, Attanath P, Sirivichayakul C, Pengsaa K, Le Mener V et al (1999) A new Vero cell rabies vaccine: results of a comparative trial with human diploid cell rabies vaccine in children. Clin Infect Dis 29(1):141\u2013149","journal-title":"Clin Infect Dis"},{"issue":"5","key":"791_CR17","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1086\/515267","volume":"177","author":"A Strady","year":"1998","unstructured":"Strady A, Lang J, Lienard M, Blondeau C, Jaussaud R, Plotkin SA (1998) Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. J Infect Dis 177(5):1290\u20131295","journal-title":"J Infect Dis"},{"issue":"3","key":"791_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.chom.2019.12.012","volume":"27","author":"F Yang","year":"2020","unstructured":"Yang F, Lin S, Ye F, Yang J, Qi J, Chen Z et al (2020) Structural analysis of rabies virus glycoprotein reveals pH-dependent conformational changes and interactions with a neutralizing antibody. Cell Host Microbe 27(3):441\u201353 e7","journal-title":"Cell Host Microbe"},{"key":"791_CR19","doi-asserted-by":"crossref","unstructured":"Stamper CT, Wilson PC (2018) What are the primary limitations in B-cell affinity maturation, and how much affinity maturation can we drive with vaccination? Is affinity maturation a self-defeating process for eliciting broad protection? Cold Spring Harb Perspect Biol 10(5)","DOI":"10.1101\/cshperspect.a028803"},{"issue":"10","key":"791_CR20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein SL, Flanagan KL (2016) Sex differences in immune responses. Nat Rev Immunol 16(10):626\u2013638","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"791_CR21","doi-asserted-by":"publisher","first-page":"16084","DOI":"10.1038\/s41598-022-20445-8","volume":"12","author":"C Kewcharoenwong","year":"2022","unstructured":"Kewcharoenwong C, Sein MM, Nithichanon A, Khongmee A, Wessells KR, Hinnouho GM et al (2022) Daily preventive zinc supplementation increases the antibody response against pathogenic Escherichia coli in children with zinc insufficiency: a randomised controlled trial. Sci Rep 12(1):16084","journal-title":"Sci Rep"}],"container-title":["Medical Microbiology and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-024-00791-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00430-024-00791-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-024-00791-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T08:05:34Z","timestamp":1735200334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00430-024-00791-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,18]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["791"],"URL":"https:\/\/doi.org\/10.1007\/s00430-024-00791-2","relation":{},"ISSN":["0300-8584","1432-1831"],"issn-type":[{"value":"0300-8584","type":"print"},{"value":"1432-1831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,18]]},"assertion":[{"value":"6 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethics committee of the Faculty of Associated Medical Sciences, Chiang Mai University (number: AMSEC-63FB-005). All participants signed an informed consent before entering the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"7"}}